First-line Chemotherapy for Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

February 6, 2022

Study Completion Date

March 13, 2022

Conditions
Recurrent Cervical CarcinomaPersistent Advanced Cervical CarcinomaChemotherapyVascular Endothelial Growth Factor 2 InhibitorApatinibTargeted Therapy
Interventions
DRUG

Chemotherapy plus apatinib

"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."

Trial Locations (1)

100730

Lei Li, Beijing

All Listed Sponsors
lead

Lei Li

OTHER

NCT04188847 - First-line Chemotherapy for Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter